Federation des caisses Desjardins du Quebec’s Lineage Cell Therapeutics LCTX Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-500	Closed	-$790	–	3094
2026 Q1	$790	Buy	+500	New	+$843	﹤0.01%	2781
2018 Q4	–	Sell	-3,429	Closed	-$7.05K	–	2117
2018 Q3	$7.05K	Hold	3,429	–	–	﹤0.01%	1812
2018 Q2	$6.18K	Hold	3,429	–	–	﹤0.01%	1864
2018 Q1	$8.07K	Hold	3,429	–	–	﹤0.01%	1759
2017 Q4	$6.45K	Hold	3,429	–	–	﹤0.01%	1815
2017 Q3	$8.52K	Hold	3,429	–	–	﹤0.01%	1714
2017 Q2	$9.45K	Buy	+3,429	New	+$9.58K	﹤0.01%	1751

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Federation des caisses Desjardins du Quebec's LCTX Position: Q2 2026 in Review

Federation des caisses Desjardins du Quebec sold out of Lineage Cell Therapeutics (LCTX) in Q2 2026, closing a stake of 500 shares — an estimated $790 sold.

Federation des caisses Desjardins du Quebec first reported a position in LCTX in Q2 2017 and held it in 7 quarters. The position peaked at $9.45K in Q2 2017. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

Federation des caisses Desjardins du Quebec reported no remaining Lineage Cell Therapeutics position as of Q2 2026 after selling out during the quarter.
Federation des caisses Desjardins du Quebec sold 500 Lineage Cell Therapeutics shares in Q2 2026, an estimated $790.
Federation des caisses Desjardins du Quebec first reported a position in Lineage Cell Therapeutics in Q2 2017 and held it in 7 quarters.
Federation des caisses Desjardins du Quebec's Lineage Cell Therapeutics position peaked at $9.45K in Q2 2017.
132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q2 2026, filed 14 Aug 2026.